ライフサイエンスコーパス: IDV

1 IDV caused minor clinical signs in the infected cattle,

2 IDV IC(50) correlated with HIV-1 RNA response after the

3 IDV-NP-BMM treatment led to robust IDV levels and reduce

4 IDV-NP-BMM was administered i.v. to mice resulting in co

5 vir (IDV)/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC.

6 nd 50% inhibitory concentrations for SQV and IDV at baseline.

7 ed into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation.

8 t and PM1 T cell lines were not inhibited by IDV.

9 istered i.v. to mice resulting in continuous IDV release for 14 days.

10 a new genus of influenza, influenzavirus D (IDV).

11 genus of influenza virus, influenzavirus D (IDV).

12 y flow (MRI) (mL/min)= 0.85 x coronary flow (IDV) (mL/min)+17 (mL/min), r=.89, and coronary flow rese

13 Indinavir (IDV) (also called CRIXIVAN, MK-639, or L-735,524) is a p

14 Indinavir (IDV) is a potent and selective human immunodeficiency vi

15 dine (ZDV), lamivudine (3TC), and indinavir (IDV), and found a significant increase in the expression

16 jects who received 36-52 weeks of indinavir (IDV)/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC.

17 rmulations of saquinavir (SQV) to indinavir (IDV) in patients with extensive hard-gel SQV experience.

18 ir (SQV) hard capsules (SQVhc) to indinavir (IDV) or saquinavir soft-gel capsules (SQVsgc) after >48

19 ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone

20 Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifi

21 Although the disease observed was mild, IDV induced neutrophil tracking and epithelial attenuati

22 Moreover, IDV did not inhibit activation of caspases-1, -3, -4, -5

23 NP-IDV-BMMs administered to HIV-1-challenged humanized mice

24 In the former, NP-IDV formulation contained within BMMs was adoptively tra

25 these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-deriv

26 We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants

27 ased on these results, and on the ability of IDV to infect and transmit in multiple mammalian species

28 estigated the effects of ex vivo addition of IDV on lymphocyte activation and apoptosis in cells from

29 To investigate the circulation of IDV among pigs in Italy, in the period between June 2015

30 initiated therapy with suboptimal dosages of IDV, we monitored the emergence of viral resistance to t

31 her our understanding of the epidemiology of IDV, real-time reverse transcription-PCR was performed o

32 acid substitutions and the observed level of IDV resistance.

33 e for two distinct cocirculating lineages of IDV which freely reassort.

34 ies to determine the pathogenic potential of IDV are warranted.

35 ollected in 2015 showed a high prevalence of IDV antibody titers (11.7%), while archive sera from 200

36 t with the near-ubiquitous seroprevalence of IDV previously found.

37 Eighty-nine subjects received IDV or SQVsgc or continued to receive SQVhc and continue

38 rve (MRI) =0.79 x coronary velocity reserve (IDV) + 0.34, r=.89.

39 IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain r

40 Tissue and sera IDV levels were greater than or equal to 50 microM for 2

41 It is concluded that IDV may prolong cell survival indirectly by inhibiting t

42 In summary, this study demonstrates that IDV causes a mild respiratory disease upon experimental

43 We also extended our previous finding that IDV-resistant viral variants exhibit various patterns of

44 The findings indicate that IDV interferes with cell-cycle progression in primary ce

45 Here, we show that IDV is common in clinical samples of bovine respiratory

46 These results suggest that IDV is common in bovines with respiratory disease and th

47 e sequencing were done; 12 codons related to IDV and SQV resistance were analyzed.

48 , 63, 71, and 90 with in vitro resistance to IDV and SQV.

49 gave rise to measurable viral resistance to IDV.

50 with HIV-1 RNA response after the switch to IDV but added little predictive power once the genotype

51 s receiving SQVhc then switched treatment to IDV.

52 thereafter, intracoronary Doppler velocity (IDV) and flow measurements were made during cardiac cath

53 Influenza D virus (IDV), a new member of the Orthomyxoviridae family, was f

54 tentatively classified as influenza D virus (IDV), was identified in swine, cattle, sheep, and goats.

55 tentatively classified as influenza D virus (IDV).

56 ted from sick animals, it is unclear whether IDV causes any clinical disease in cattle.

57 blood mononuclear cell (PBMC) cultures with IDV resulted in a dose-dependent inhibition of lymphopro

58 from baseline was significantly greater with IDV and was inversely correlated with the number of prot

59 how that cattle experimentally infected with IDV can shed virus and transmit it to other cattle throu

60 idual pens were inoculated intranasally with IDV strain D/bovine/Mississippi/C00046N/2014.